Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report.
Primary peritoneal papillary serous adenocarcinoma is histologically identical to ovarian papillary serous adenocarcinoma. This diagnosis is made if the ovaries are of normal size with either no tumor or only minimal surface involvement. We describe a patient with a primary peritoneal papillary serous adenocarcinoma which was resistant to initial therapy with paclitaxel, but subsequently achieved a partial response with carboplatin-based chemotherapy. Accordingly, carboplatin therapy should be considered in paclitaxel resistant primary peritoneal papillary serous carcinoma.
Herrada
J
J
Sierra Medical Center, Department of Medical Oncology, El Paso, Texas, USA.
Kudelka
A P
AP
Tornos
C
C
Shin
D M
DM
Kavanagh
J J
JJ
Edwards
C L
CL
Verschraegen
C F
CF
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel